Article info
PDFInflammatory bowel disease
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- Correspondence to Dr Freddy Cornillie, Department of Immunology, Janssen Biologics BV, Archimedesweg 29, 2333 CM Leiden, The Netherlands; fcornill{at}its.jnj.com
Citation
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Publication history
- Received November 5, 2012
- Revised January 6, 2014
- Accepted January 7, 2014
- First published January 28, 2014.
Online issue publication
October 28, 2016
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
- latest version (26 October 2017).
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/